D.E. Shaw & Co
KNSA icon

D.E. Shaw & Co’s Kiniksa Pharmaceuticals KNSA Stock Holding History

D.E. Shaw & Co’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.4M Sell
569,756
-389,501
-41% -$20.2M 0.02% 941
2026
Q1 		$46.2M Sell
959,257
-282,364
-23% -$12.5M 0.03% 692
2025
Q4 		$51.2M Buy
1,241,621
+107,435
+9% +$4.31M 0.03% 684
2025
Q3 		$44M Buy
1,134,186
+342,881
+43% +$11.1M 0.02% 721
2025
Q2 		$21.9M Buy
791,305
+393,560
+99% +$10M 0.02% 978
2025
Q1 		$8.83M Buy
397,745
+77,738
+24% +$1.6M 0.01% 1489
2024
Q4 		$6.33M Sell
320,007
-990
-0.3% -$22.6K ﹤0.01% 1796
2024
Q3 		$8.02M Buy
320,997
+151,349
+89% +$3.69M 0.01% 1582
2024
Q2 		$3.17M Sell
169,648
-52,205
-24% -$978K ﹤0.01% 2225
2024
Q1 		$4.38M Sell
221,853
-82,752
-27% -$1.62M ﹤0.01% 1992
2023
Q4 		$5.34M Sell
304,605
-12,914
-4% -$212K ﹤0.01% 1855
2023
Q3 		$5.52M Buy
317,519
+78,919
+33% +$1.33M 0.01% 1729
2023
Q2 		$3.36M Sell
238,600
-1,188
-0.5% -$15.9K ﹤0.01% 2197
2023
Q1 		$2.58M Buy
239,788
+2,343
+1% +$30.9K ﹤0.01% 2491
2022
Q4 		$3.56M Buy
237,445
+125,274
+112% +$1.82M ﹤0.01% 2408
2022
Q3 		$1.44M Buy
112,171
+69,243
+161% +$789K ﹤0.01% 3293
2022
Q2 		$416K Buy
+42,928
New +$401K ﹤0.01% 4205
2022
Q1 		– Sell
-12,317
Closed -$145K – 5760
2021
Q4 		$145K Buy
+12,317
New +$151K ﹤0.01% 4978
2021
Q1 		– Sell
-50,089
Closed -$885K – 4276
2020
Q4 		$885K Sell
50,089
-52,297
-51% -$919K ﹤0.01% 3094
2020
Q3 		$1.57M Buy
102,386
+53,004
+107% +$995K ﹤0.01% 2558
2020
Q2 		$1.26M Buy
+49,382
New +$1.03M ﹤0.01% 2768
2019
Q3 		– Sell
-26,134
Closed -$354K – 3919
2019
Q2 		$354K Sell
26,134
-69,122
-73% -$1.07M ﹤0.01% 3243
2019
Q1 		$1.72M Buy
95,256
+85,714
+898% +$1.66M ﹤0.01% 2267
2018
Q4 		$268K Buy
+9,542
New +$199K ﹤0.01% 3413

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

D.E. Shaw & Co's KNSA Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Kiniksa Pharmaceuticals (KNSA) stake by 41% in Q2 2026, selling an estimated $20.2M and leaving 569,756 shares worth $36.4M. The position accounts for 0.02% of the portfolio, ranked #941.

D.E. Shaw & Co first reported a position in KNSA in Q4 2018 and has held it in 24 quarters since. The position peaked at $51.2M in Q4 2025. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • D.E. Shaw & Co held 569,756 shares of Kiniksa Pharmaceuticals worth $36.4M as of Q2 2026.
  • D.E. Shaw & Co sold 389,501 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $20.2M.
  • Kiniksa Pharmaceuticals made up 0.02% of D.E. Shaw & Co's portfolio in Q2 2026, its #941 holding.
  • D.E. Shaw & Co first reported a position in Kiniksa Pharmaceuticals in Q4 2018 and has held it in 24 quarters since.
  • D.E. Shaw & Co's Kiniksa Pharmaceuticals position peaked at $51.2M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.